{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:39:51Z","timestamp":1788921591757,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,15]]},"DOI":"10.7759\/cureus.96931","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:23:37Z","timestamp":1763270617000},"source":"Crossref","is-referenced-by-count":1,"title":["Redefining Early Diabetic Kidney Disease Management: A Critical Review of Practice Patterns and Missed Opportunities in Real-World Settings"],"prefix":"10.7759","author":[{"given":"Abdullah","family":"Almalki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic RZ","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017, 12:2032-45. 10.2215\/CJN.11491116","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian M","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, Heagerty PJ, Tuttle K, Weiss NS, de Boer IH. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. 2016, 316:602-10. 10.1001\/jama.2016.10924","journal-title":"JAMA"},{"key":"ref3","unstructured":"IDF Diabetes Atlas. International Diabetes Federation. ( 2024). Accessed. November 4, 2025: https:\/\/diabetesatlas.org\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_394_22","article-title":"Prevalence of type 2 diabetes mellitus in the general population of Saudi Arabia, 2000-2020: a systematic review and meta-analysis of observational studies","volume":"11","author":"Jarrar M","year":"2023","unstructured":"Jarrar M, Abusalah MA, Albaker W, et al.. Prevalence of type 2 diabetes mellitus in the general population of Saudi Arabia, 2000-2020: a systematic review and meta-analysis of observational studies. Saudi J Med Med Sci. 2023, 11:1-10. 10.4103\/sjmms.sjmms_394_22","journal-title":"Saudi J Med Med Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.443","article-title":"Change in the estimated glomerular filtration rate over time and risk of all-cause mortality","volume":"83","author":"Turin TC","year":"2013","unstructured":"Turin TC, Coresh J, Tonelli M, et al.. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int. 2013, 83:684-91. 10.1038\/ki.2012.443","journal-title":"Kidney Int"},{"key":"ref6","unstructured":"CKD evaluation and management. Kidney Disease. Improving Global Outcomes (KDIGO). (2024). https:\/\/kdigo.org\/guidelines\/ckd-evaluation-and-management\/."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S003","article-title":"3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. 3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2024. Diabetes Care. 2024, 47:S43-51. 10.2337\/dc24-S003","journal-title":"Diabetes Care"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink HJ","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, et al.. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020, 383:1436-46. 10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris GL","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al.. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020, 383:2219-29. 10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.68584","article-title":"The pattern of practice in the management of early diabetic kidney disease","volume":"16","author":"Almalki AH","year":"2024","unstructured":"Almalki AH, Sadagah LF, Makeen A, et al.. The pattern of practice in the management of early diabetic kidney disease. Cureus. 2024, 16:e68584. 10.7759\/cureus.68584","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1002\/j.2040-4603.2011.tb00365.x","article-title":"Pathophysiology of the diabetic kidney","volume":"1","author":"Vallon V","year":"2011","unstructured":"Vallon V, Komers R. Pathophysiology of the diabetic kidney. Comprehensive Physiology. 2011, 1:1175-32.","journal-title":"Comprehensive Physiology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.10.042","article-title":"Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study","volume":"133","author":"Fangel MV","year":"2020","unstructured":"Fangel MV, Nielsen PB, Kristensen JK, Larsen TB, Overvad TF, Lip GY, Jensen MB. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study. Am J Med. 2020, 133:e269-79. 10.1016\/j.amjmed.2019.10.042","journal-title":"Am J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.531","article-title":"Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes","volume":"80","author":"Gansevoort RT","year":"2011","unstructured":"Gansevoort RT, Matsushita K, van der Velde M, et al.. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. Kidney Int. 2011, 80:93-104. 10.1038\/ki.2010.531","journal-title":"Kidney Int"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer HJ","year":"2003","unstructured":"Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003, 289:3273-7. 10.1001\/jama.289.24.3273","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer IH","year":"2022","unstructured":"de Boer IH, Khunti K, Sadusky T, et al.. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022, 45:3075-90. 10.2337\/dci22-0027","journal-title":"Diabetes Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz N","year":"2021","unstructured":"Stempniewicz N, Vassalotti JA, Cuddeback JK, et al.. Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations. Diabetes Care. 2021, 44:2000-9. 10.2337\/dc20-2715","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2021.07.003","article-title":"Improving frequency of urinary albumin testing in type 2 diabetes in primary care - an analysis of cross-sectional studies in Denmark","volume":"15","author":"Persson F","year":"2021","unstructured":"Persson F, Charles M, Povlsen JV, Knudsen ST. Improving frequency of urinary albumin testing in type 2 diabetes in primary care - an analysis of cross-sectional studies in Denmark. Prim Care Diabetes. 2021, 15:1007-11. 10.1016\/j.pcd.2021.07.003","journal-title":"Prim Care Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088956","article-title":"Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study","volume":"9","author":"Al-Rubeaan K","year":"2014","unstructured":"Al-Rubeaan K, Youssef AM, Subhani SN, et al.. Diabetic nephropathy and its risk factors in a society with a type 2 diabetes epidemic: a Saudi National Diabetes Registry-based study. PLoS One. 2014, 9:e88956. 10.1371\/journal.pone.0088956","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic V","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al.. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019, 380:2295-306. 10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker TA","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al.. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a meta-analysis of cardiovascular outcome trials. Lancet. 2019, 393:31-9. 10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, et al.. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023, 388:117-27. 10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt B","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al.. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021, 385:2252-63. 10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal R","year":"2021","unstructured":"Agarwal R, Filippatos G, Pitt B, et al.. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2021, 43:474-84. 10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2014.07.002","article-title":"Socioeconomic disparities in chronic kidney disease","volume":"22","author":"Nicholas SB","year":"2015","unstructured":"Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis. 2015, 22:6-15. 10.1053\/j.ackd.2014.07.002","journal-title":"Adv Chronic Kidney Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.10704","article-title":"Quality of chronic kidney disease management in Canadian primary care","volume":"2","author":"Bello AK","year":"2019","unstructured":"Bello AK, Ronksley PE, Tangri N, et al.. Quality of chronic kidney disease management in Canadian primary care. JAMA Netw Open. 2019, 2:e1910704. 10.1001\/jamanetworkopen.2019.10704","journal-title":"JAMA Netw Open"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.05.029","article-title":"Electronic consultations in nephrology: pilot implementation and evaluation","volume":"68","author":"Mendu ML","year":"2016","unstructured":"Mendu ML, McMahon GM, Licurse A, Solomon S, Greenberg J, Waikar SS. Electronic consultations in nephrology: pilot implementation and evaluation. Am J Kidney Dis. 2016, 68:821-3. 10.1053\/j.ajkd.2016.05.029","journal-title":"Am J Kidney Dis"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-6686.2012.00323.x","article-title":"Challenges perceived by primary care providers to educating patients about chronic kidney disease","volume":"38","author":"Greer RC","year":"2012","unstructured":"Greer RC, Crews DC, Boulware LE. Challenges perceived by primary care providers to educating patients about chronic kidney disease. J Ren Care. 2012, 38:174-81. 10.1111\/j.1755-6686.2012.00323.x","journal-title":"J Ren Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.86","article-title":"Early detection of CKD: the benefits, limitations and effects on prognosis","volume":"7","author":"Levin A","year":"2011","unstructured":"Levin A, Stevens P. Early detection of CKD: the benefits, limitations and effects on prognosis. Nat Rev Nephrol. 2011, 7:446-57. 10.1038\/nrneph.2011.86","journal-title":"Nat Rev Nephrol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2019.11.001","article-title":"Kidney health for everyone everywhere - From prevention to detection and equitable access to care","volume":"40","author":"29.\tLi PK","year":"2020","unstructured":"29.\tLi PK, Garcia-Garcia G, Lui SF, et al.. Kidney health for everyone everywhere - From prevention to detection and equitable access to care. Nefrologia (Engl Ed). 2020, 40:133-41. 10.1016\/j.nefro.2019.11.001","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15678","article-title":"Machine learning for prediction of chronic kidney disease progression: validation of the Klinrisk model in the CANVAS Program and CREDENCE trial","volume":"26","author":"Tangri N","year":"2024","unstructured":"Tangri N, Ferguson TW, Bamforth RJ, et al.. Machine learning for prediction of chronic kidney disease progression: validation of the Klinrisk model in the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2024, 26:3371-80. 10.1111\/dom.15678","journal-title":"Diabetes Obes Metab"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01416-2","article-title":"Optimizing multidisciplinary care of patients with chronic kidney disease and type 2 diabetes mellitus","volume":"14","author":"Kelepouris E","year":"2023","unstructured":"Kelepouris E, St. Peter W, Neumiller JJ, Wright EE. Optimizing multidisciplinary care of patients with chronic kidney disease and type 2 diabetes mellitus. Diabetes Ther. 2023, 14:1111-36. 10.1007\/s13300-023-01416-2","journal-title":"Diabetes Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey AS","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, et al.. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014, 64:821-35. 10.1053\/j.ajkd.2014.07.030","journal-title":"Am J Kidney Dis"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-020-01656-9","article-title":"Novel biomarkers of diabetic kidney disease: current status and potential clinical application","volume":"58","author":"33.\tBarutta F","year":"2021","unstructured":"33.\tBarutta F, Bellini S, Canepa S, Durazzo M, Gruden G. Novel biomarkers of diabetic kidney disease: current status and potential clinical application. Acta Diabetol. 2021, 58:819-30. 10.1007\/s00592-020-01656-9","journal-title":"Acta Diabetol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426851-redefining-early-diabetic-kidney-disease-management-a-critical-review-of-practice-patterns-and-missed-opportunities-in-real-world-settings","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T05:23:40Z","timestamp":1763270620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426851-redefining-early-diabetic-kidney-disease-management-a-critical-review-of-practice-patterns-and-missed-opportunities-in-real-world-settings"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.96931","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,15]]}}}